[Form 3] Arrowhead Research Corporation Initial Statement of Beneficial Ownership
Daniel Joseph Apel, Chief Financial Officer of Arrowhead Pharmaceuticals (ARWR), reported direct beneficial ownership of 101,200 shares of common stock. The filing specifies that this total includes 100,000 restricted stock units that will vest over four years, disclosed on an initial Form 3.
Daniel Joseph Apel, direttore finanziario (CFO) di Arrowhead Pharmaceuticals (ARWR), ha dichiarato la titolarit脿 diretta di 101.200 azioni ordinarie. La comunicazione precisa che questo totale comprende 100.000 unit脿 azionarie vincolate che matureranno nell'arco di quattro anni, come indicato nel Modulo 3 iniziale.
Daniel Joseph Apel, director financiero de Arrowhead Pharmaceuticals (ARWR), inform贸 la titularidad directa de 101.200 acciones ordinarias. La presentaci贸n especifica que este total incluye 100.000 unidades de acciones restringidas que se consolidar谩n a lo largo de cuatro a帽os, divulgadas en un Formulario 3 inicial.
Daniel Joseph Apel鞚� Arrowhead Pharmaceuticals(ARWR)鞚� 斓滉碃鞛毂呾瀯鞛�(CFO)搿滌劀 氤错喌欤检棎 雽�頃� 101,200欤�鞚� 歆侅爲鞝� 鞚挫澋靻岇湢毳� 鞁犼碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 鞚� 齑濌硠臧� 4雲勳棎 瓯胳硱 氩犾姢韺呺悩電� 100,000臧滌潣 鞝滍暅欤检嫕雼渼(RSU)毳� 韽暔頃滊嫟瓿� 氇呾嫓霅橃柎 鞛堨溂氅�, 鞚措姅 齑堦赴 Form 3鞐� 瓿店皽霅橃棃鞀惦媹雼�.
Daniel Joseph Apel, directeur financier d'Arrowhead Pharmaceuticals (ARWR), a d茅clar茅 la propri茅t茅 b茅n茅ficiaire directe de 101 200 actions ordinaires. Le d茅p么t pr茅cise que ce total comprend 100 000 unit茅s d'actions restreintes qui seront acquises sur quatre ans, divulgu茅es dans un Formulaire 3 initial.
Daniel Joseph Apel, Chief Financial Officer von Arrowhead Pharmaceuticals (ARWR), meldete eine direkte wirtschaftliche Eigent眉merschaft von 101.200 Aktien des Stammkapitals. Die Einreichung gibt an, dass diese Summe 100.000 Restricted Stock Units (RSUs) umfasst, die 眉ber vier Jahre vesten sollen; dies wurde in einem initialen Formular 3 offengelegt.
- Direct beneficial ownership of 101,200 shares reported by the CFO, providing transparency on insider holdings.
- Includes 100,000 restricted stock units vesting over four years, which aligns CFO compensation with long-term shareholder interests.
- None.
Insights
TL;DR CFO holds 101,200 ARWR shares, incl. 100,000 RSUs vesting over four years; routine disclosure with neutral immediate market impact.
The Form 3 reports a direct ownership stake of 101,200 common shares by CFO Daniel Apel, of which 100,000 are restricted stock units with a four-year vesting schedule. This is an initial insider disclosure under Section 16 and represents equity compensation rather than an open-market purchase or sale. The information is relevant for assessing management share alignment but does not, by itself, indicate a material change to the company's capital structure or immediate valuation.
TL;DR Significant RSU grant aligns CFO incentives with shareholders; filing is standard governance disclosure without red flags.
The filing shows direct beneficial ownership and a sizable restricted equity award: 100,000 RSUs vesting over four years. From a governance perspective, multi-year vesting schedules are common to promote retention and long-term alignment. The form shows no derivative holdings and no indication of indirect ownership structures. No governance concerns are evident from the disclosure alone.
Daniel Joseph Apel, direttore finanziario (CFO) di Arrowhead Pharmaceuticals (ARWR), ha dichiarato la titolarit脿 diretta di 101.200 azioni ordinarie. La comunicazione precisa che questo totale comprende 100.000 unit脿 azionarie vincolate che matureranno nell'arco di quattro anni, come indicato nel Modulo 3 iniziale.
Daniel Joseph Apel, director financiero de Arrowhead Pharmaceuticals (ARWR), inform贸 la titularidad directa de 101.200 acciones ordinarias. La presentaci贸n especifica que este total incluye 100.000 unidades de acciones restringidas que se consolidar谩n a lo largo de cuatro a帽os, divulgadas en un Formulario 3 inicial.
Daniel Joseph Apel鞚� Arrowhead Pharmaceuticals(ARWR)鞚� 斓滉碃鞛毂呾瀯鞛�(CFO)搿滌劀 氤错喌欤检棎 雽�頃� 101,200欤�鞚� 歆侅爲鞝� 鞚挫澋靻岇湢毳� 鞁犼碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 鞚� 齑濌硠臧� 4雲勳棎 瓯胳硱 氩犾姢韺呺悩電� 100,000臧滌潣 鞝滍暅欤检嫕雼渼(RSU)毳� 韽暔頃滊嫟瓿� 氇呾嫓霅橃柎 鞛堨溂氅�, 鞚措姅 齑堦赴 Form 3鞐� 瓿店皽霅橃棃鞀惦媹雼�.
Daniel Joseph Apel, directeur financier d'Arrowhead Pharmaceuticals (ARWR), a d茅clar茅 la propri茅t茅 b茅n茅ficiaire directe de 101 200 actions ordinaires. Le d茅p么t pr茅cise que ce total comprend 100 000 unit茅s d'actions restreintes qui seront acquises sur quatre ans, divulgu茅es dans un Formulaire 3 initial.
Daniel Joseph Apel, Chief Financial Officer von Arrowhead Pharmaceuticals (ARWR), meldete eine direkte wirtschaftliche Eigent眉merschaft von 101.200 Aktien des Stammkapitals. Die Einreichung gibt an, dass diese Summe 100.000 Restricted Stock Units (RSUs) umfasst, die 眉ber vier Jahre vesten sollen; dies wurde in einem initialen Formular 3 offengelegt.
FAQ
How many ARWR shares does Daniel Joseph Apel report owning?
Does the Form 3 disclose restricted stock units for the ARWR CFO?
Are any derivative securities reported for ARWR on this Form 3?
What role at ARWR is listed for the reporting person?
Is the reported ownership direct or indirect?
